Vagus nerve stimulation market seen nearly doubling by 2032

By AI, Created 10:31 AM UTC, June 01, 2026, /AGP/ – Persistence Market Research says the global vagus nerve stimulation market will grow from $542.3 million in 2025 to $1.01 billion by 2032, driven by rising neurological disorder cases, wider neuromodulation adoption, and demand for minimally invasive therapies. North America leads now, while Asia Pacific is emerging as a growth market.

Why it matters: - Vagus nerve stimulation is moving from a niche therapy to a broader treatment option for epilepsy, depression and other hard-to-treat neurological conditions. - The market’s growth points to stronger demand for minimally invasive neuromodulation devices as healthcare systems look for alternatives that can improve patient outcomes. - The category could gain added relevance as neurological disease burdens rise and clinical use expands.

What happened: - Persistence Market Research valued the global vagus nerve stimulation market at $542.3 million in 2025. - The market is projected to reach $1,013.4 million by 2032. - The forecast implies a 9.3% compound annual growth rate from 2025 to 2032. - The report was released in Brenford, London, United Kingdom, on June 1, 2026. - The report is available as a free sample, with customization options and a full report purchase page.

The details: - Implantable devices lead the market because of clinical effectiveness and long-term benefits. - External stimulation devices also make up a product segment, but they trail implantable systems in adoption. - The main applications include epilepsy, depression, neurological disorders and migraine management. - Hospitals, specialty clinics and neurological treatment centers are the main end users. - North America remains the largest regional market because of advanced healthcare infrastructure, higher spending and strong adoption of innovative neurological treatments. - Asia Pacific is emerging as a growth region as healthcare access improves, awareness of neurostimulation rises and investment increases. - The report says rising neurological disease prevalence is a key demand driver. - Technological advances in implantable devices are helping expand clinical applications and improve treatment outcomes.

Between the lines: - The forecast suggests the market is benefiting from both medical need and technology improvement, not just one factor. - High treatment costs and surgical complexity remain barriers, especially in regions with less mature healthcare systems. - The presence of major device makers such as LivaNova PLC, electroCore Inc., Medtronic plc, Boston Scientific Corporation, NeuroSigma Inc., tVNS Technologies GmbH and Parasym Ltd. points to a competitive market with established medtech players.

What’s next: - Growth will likely depend on whether manufacturers can make stimulation devices easier to access and less costly to deploy. - Wider physician acceptance and expanding therapeutic uses could support continued adoption through 2032. - Regional growth beyond North America will likely hinge on reimbursement, infrastructure and clinical uptake in emerging markets.

The bottom line: - Vagus nerve stimulation is on track for steady, double-digit-style expansion as neurological care shifts toward targeted, device-based therapies.